Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

NCT03710772 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

51

Enrollment

OTHER

Sponsor class

Conditions

Mantle Cell Lymphoma

Interventions

DRUG: Cyclophosphamide
DRUG: Cytarabine
DRUG: Dexamethasone
DRUG: Doxorubicin Hydrochloride
DRUG: Ibrutinib
DRUG: Methotrexate
BIOLOGICAL: Rituximab
DRUG: Venetoclax
DRUG: Vincristine Sulfate

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]